SCHEMBL20135182

SCHEMBL20135182

CC(C)(C)C1(c2ccc(C(=O)O)cn2)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 11/20 0.41
P4HA1 P13674 2/20 0.39
P4HTM Q9NXG6 2/20 0.39
MIF P14174 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
PPARG P37231 1/20 0.38
RXRG P48443 1/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135620 0.80 B3GNT2 (0.34) MAPT
SCHEMBL20134813 0.79 RXRA (0.38) RARBRARGRXRARXRBRXRG
SCHEMBL20135313 0.72 HPGD (0.38) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL20134968 0.70 CA12 (0.47) RARARARBRARGRXRA
SCHEMBL20134906 0.69 CA1 (0.37) RARBRARGRXRARXRBRXRG
SCHEMBL20135162 0.67 SRD5A2 (0.38) RXRARXRBRXRGALDH1A1CYP2C9
SCHEMBL20135357 0.67 RARA (0.44) HCAR3P4HA1P4HTMMIFRARA
SCHEMBL542191 0.66 CYP2C9 (0.53) ALDH1A1CYP2C9MAPT
SCHEMBL28384854 0.66 RXRA (0.56) HCAR3P4HA1P4HTMMIFRARA
SCHEMBL20135320 0.66 CA1 (0.34) HCAR3RXRARXRBRXRGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 HCAR3 532/4885P4HA1 840/4885P4HTM 857/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 HCAR3 745/4885P4HA1 801/4885P4HTM 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.